GlassScriptPhysician profile
Michael V Baldwin
NPI 1780618371
$12,108.75
in general payments reported to CMS, 2019-2025
60 companies · $2,941 in 2025
The $2,941 reported for 2025 was more than what 98% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,877 · 2022: $2,187 · 2023: $2,034 · 2024: $2,070 · 2025: $2,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,044.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,588.01 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,196.80 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,005.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $701.60 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $690.37 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $577.79 | 2021-2025 | |
| Abbvie INC. | $567.90 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $413.06 | 2021-2024 | |
| Axsome Therapeutics, INC. | $293.25 | 2023-2025 | Auvelity, Sunosi |
| Idorsia Pharmaceuticals US INC | $277.81 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $271.67 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.58 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $244.92 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $212.98 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $202.34 | 2021-2024 | Nexletol |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $197.53 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $178.87 | 2021-2025 | Vpriv |
| Kowa Pharmaceuticals America, INC. | $178.76 | 2021-2023 | Livalo, Seglentis |
| Exact Sciences Corporation | $171.89 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $169.19 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $157.27 | 2024-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $155.54 | 2024-2025 | Zenpep |
| Amarin Pharma, INC. | $154.91 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $153.88 | 2023-2025 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.52 | 2021-2025 | Jardiance, Spiriva Respimat |
| Braeburn INC. | $143.96 | 2025 | Brixadi |
| Arbor Pharmaceuticals, INC. | $140.86 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $137.85 | 2021-2022 | |
| Tolmar, INC. | $125.67 | 2024-2025 | Jatenzo |
| Abbott Laboratories | $120.35 | 2023-2025 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $97.11 | 2023-2025 | Edarbi, Edarbi, Azmiro |
| Bayer Healthcare Pharmaceuticals INC. | $92.13 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $91.77 | 2021-2023 | |
| Dexcom, INC. | $91.39 | 2023-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $83.57 | 2021-2023 | Yupelri |
| Astellas Pharma US INC | $75.61 | 2021-2025 | Veozah |
| Alkermes, INC. | $69.32 | 2022-2025 | Aristada, Lybalvi |
| Biohaven Pharmaceuticals, INC. | $63.00 | 2021 | |
| Genzyme Corporation | $54.52 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.26 | 2022 | |
| Antares Pharma, INC. | $48.35 | 2021-2025 | Xyosted |
| Indivior INC. | $48.20 | 2024-2025 | Sublocade |
| Orexo US, INC. | $46.31 | 2023-2025 | Zubsolv |
| Eisai INC. | $44.63 | 2021 | |
| Lundbeck LLC | $34.98 | 2022-2023 | Vyepti |
| Bausch Health US, LLC | $31.29 | 2024-2025 | Aplenzin, Wellbutrin |
| Rhythm Pharmaceuticals, INC. | $29.93 | 2021 | |
| Averitas Pharma INC. | $25.63 | 2023 | Qutenza |
| Merck Sharp & Dohme LLC | $25.59 | 2021-2022 | |
| Oyster Point Pharma, INC. | $25.32 | 2023 | Tyrvaya |
| Viatris Specialty LLC | $20.86 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $19.22 | 2024 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $17.82 | 2025 | Givlaari |
| Gilead Sciences, INC. | $15.57 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.95 | 2022 | |
| Radius Health, INC. | $13.80 | 2024 | Tymlos |
| Genentech USA, INC. | $13.18 | 2021 | |
| Almatica Pharma LLC | $13.14 | 2021 | |
| Sanofi Pasteur INC. | $12.99 | 2021 | |
| Phadia US INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baldwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.